Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate

Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate in Patient With Rare Tumor (Phase I Study)

The purpose of this study is to determine the maximum tolerated dose of imatinib mesylate, given in association with a fixed dose of cyclophosphamide (50 mg bid).

Inclusion Criteria:

• Rare tumor
• metastatic disease or locally advanced disease, inoperable, with no standard treatment
• At least 28 days since the prior treatment
• Measurable disease with at least one measurable lesion

Exclusion Criteria:

• Medullary insufficiency
• Cystitis, haemorrhagic cystitis
• Hepatic porphyria